Biosergen completes the third cohort of BSG005 phase I trial
August 26, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the Safety Review Committee has decided to continue the trial with cohort 4 in the Single Ascending Dose part of BSG005’s phase I trial.BSG005 is Biosergen’s lead development compound. It is a novel anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains, which make them unique within all antifungal drug classes. The successful completion of the phase I trials will demonstrate, that BSG005